CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights

被引：0

作者：

Cao, Li-Ya ^{[1
]}

Zhao, Yue ^{[1
]}

Chen, Yang ^{[2
]}

Ma, Pan ^{[1
]}

Xie, Jiang-Chuan ^{[1
]}

Pan, Xin-Mei ^{[1
]}

Zhang, Xin ^{[1
]}

Chen, Yong-Chuan ^{[1
]}

Wang, Qian ^{[1
]}

Xie, Lin-Li ^{[1
]}

机构：

[1] Third Mil Med Univ, Army Med Univ, Affiliated Hosp 1, Dept Pharm, Chongqing, Peoples R China

[2] Chongqing Univ, Chongqing Emergency Med Ctr, Pharm Dept, Cent Hosp, Chongqing, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

关键词：

chimeric antigen receptor T-cell; clinical trials; clinicaltrials.gov; hematological malignancies; solid tumors; publication following search queries: condition/disease or intervention/treatment: "CAR T; chimeric antigen receptor; CAR T cell; RESISTANCE;

D O I：

10.3389/fimmu.2025.1583116

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor T (CAR-T) cell therapy has undergone vigorous development in recent years, yet it still faces significant challenges and difficulties in its clinical application and further development. A systematic synthesis of global trends in CAR-T clinical trials is essential to identify knowledge gaps, optimize treatment strategies, and guide future research directions. This review analyzed 1,580 CAR-T clinical trials registered at ClinicalTrials.gov as of April 2024, and extracted characteristic data in multiple dimensions, including target specificity, treatment indication, and development stage etc. The transparency of trial outcomes was assessed by validation with articles published in PubMed/Google Scholar. Additionally, it is complemented by investigator surveys assessing to barriers to CAR-T development, prospects, and recommendations.

引用

页数：13

共 60 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells [J].

Agarwal, Sangya ;

Aznar, M. Angela ;

Rech, Andrew J. ;

Good, Charly R. ;

Kuramitsu, Shunichiro ;

Da, Tong ;

Gohil, Mercy ;

Chen, Linhui ;

Hong, Seok-Jae Albert ;

Ravikumar, Pranali ;

Rennels, Austin K. ;

Salas-Mckee, January ;

Kong, Weimin ;

Ruella, Marco ;

Davis, Megan M. ;

Plesa, Gabriela ;

Fraietta, Joseph A. ;

Porter, David L. ;

Young, Regina M. ;

June, Carl H. .

IMMUNITY, 2023, 56 (10) :2388-2407.e9

[3] Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia [J].

Atar, Daniel ;

Ruoff, Lara ;

Mast, Anna-Sophia ;

Krost, Simon ;

Moustafa-Oglou, Moustafa ;

Scheuermann, Sophia ;

Kristmann, Beate ;

Feige, Maximilian ;

Canak, Ayseguel ;

Wolsing, Kathrin ;

Schlager, Lennart ;

Schilbach, Karin ;

Zekri, Latifa ;

Ebinger, Martin ;

Nixdorf, Daniel ;

Subklewe, Marion ;

Schulte, Johannes ;

Lengerke, Claudia ;

Jeremias, Irmela ;

Werchau, Niels ;

Mittelstaet, Joerg ;

Lang, Peter ;

Handgretinger, Rupert ;

Schlegel, Patrick ;

Seitz, Christian M. .

LEUKEMIA, 2024, 38 (10) :2183-2195

[4] Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis [J].

Bajwa, Amneet ;

Zhao, Qiuhong ;

Geer, Marcus ;

Lin, Chenyu ;

Westholder, James ;

Maakaron, Joseph ;

Ghosh, Monalisa ;

Frame, David ;

Galal, Ahmed ;

Tossey, Justin ;

Ahmed, Nausheen ;

Bezerra, Evandro ;

Denlinger, Nathan ;

de Lima, Marcos ;

Epperla, Narendranath ;

Caimi, Paolo ;

Voorhees, Timothy .

BLOOD ADVANCES, 2025, 9 (01) :170-175

[5] Current understanding and management of CAR T cell-associated toxicities [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (07) :501-521

[6] Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment [J].

Chen, Qiuhong ;

Sun, Yang ;

Li, Hua .

DISCOVER ONCOLOGY, 2024, 15 (01)

[7] A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma [J].

Chen, Xinfeng ;

Li, Xin ;

Liu, Yanfen ;

Zhang, Zhen ;

Zhang, Xudong ;

Huang, Jianmin ;

Li, Hong ;

Li, Feng ;

Zhang, Lei ;

Li, Ling ;

Wu, Xiaolong ;

Ma, Wang ;

Sun, Zhenchang ;

Yu, Hui ;

Zhou, Zhiyuan ;

Feng, Xiaoyan ;

Cui, Kang ;

Li, Zhaoming ;

Zhang, Hongling ;

Zeng, Ying ;

Wan, Xiaochun ;

Chen, Youhai H. ;

Zhang, Mingzhi ;

Zhang, Yi .

IMMUNOTHERAPY, 2020, 12 (10) :681-696

[8] Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy [J].

Chong, Elise A. ;

Alanio, Cecile ;

Svoboda, Jakub ;

Nasta, Sunita D. ;

Landsburg, Daniel J. ;

Lacey, Simon F. ;

Ruella, Marco ;

Bhattacharyya, Siddharth ;

Wherry, E. John ;

Schuster, Stephen J. .

BLOOD, 2022, 139 (07) :1026-1038

[9] Chimeric antigen receptor T cell therapy for autoimmune disease [J].

Chung, James B. ;

Brudno, Jennifer N. ;

Borie, Dominic ;

Kochenderfer, James N. .

NATURE REVIEWS IMMUNOLOGY, 2024, 24 (11) :830-845

[10] γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-inhuman trial [J].

Cowan, Andrew J. ;

Pont, Margot J. ;

Sather, Blythe ;

Turtle, Cameron J. ;

Till, Brian G. ;

Libby, Edward N. ;

Coffey, David G. ;

Tuazon, Sherilyn A. ;

Wood, Brent ;

Gooley, Ted ;

Wu, Vicky Q. ;

Voutsinas, Jenna ;

Song, Xiaoling ;

Shadman, Mazyar ;

Gauthier, Jordan ;

Chapuis, Aude G. ;

Milano, Filippo ;

Maloney, David G. ;

Riddell, Stanley R. ;

Green, Damian J. .

LANCET ONCOLOGY, 2023, 24 (07) :811-822

← 1 2 3 4 5 6 →